Clinical Trial Update: PDR001 Plus Imatinib for Metastatic or Unresectable GIST [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of PDR001 plus imatinib in metastatic or unresectable gastrointestinal stromal tumors completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Imatinib (imatinib)
• PDR001

Snippet

Sponsor: Asan Medical Center | Conditions: Gastrointestinal Stromal Tumors | Phase 1, Phase 2 | Status: COMPLETED